Your browser doesn't support javascript.
loading
ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model.
Vandyck, Koen; Abdelnabi, Rana; Gupta, Kusum; Jochmans, Dirk; Jekle, Andreas; Deval, Jerome; Misner, Dinah; Bardiot, Dorothée; Foo, Caroline S; Liu, Cheng; Ren, Suping; Beigelman, Leonid; Blatt, Lawrence M; Boland, Sandro; Vangeel, Laura; Dejonghe, Steven; Chaltin, Patrick; Marchand, Arnaud; Serebryany, Vladimir; Stoycheva, Antitsa; Chanda, Sushmita; Symons, Julian A; Raboisson, Pierre; Neyts, Johan.
Afiliação
  • Vandyck K; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium. Electronic address: kvandyck@aligos.com.
  • Abdelnabi R; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
  • Gupta K; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA.
  • Jochmans D; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
  • Jekle A; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA.
  • Deval J; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA.
  • Misner D; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA.
  • Bardiot D; CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium.
  • Foo CS; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
  • Liu C; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA.
  • Ren S; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA.
  • Beigelman L; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA.
  • Blatt LM; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA.
  • Boland S; CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium.
  • Vangeel L; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
  • Dejonghe S; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
  • Chaltin P; Centre for Drug Design and Discovery (CD3), KU Leuven, Gaston Geenslaan 2, 3001 Leuven, Belgium; CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium.
  • Marchand A; CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium.
  • Serebryany V; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA.
  • Stoycheva A; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA.
  • Chanda S; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA.
  • Symons JA; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA.
  • Raboisson P; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium.
  • Neyts J; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium. Electronic address: johan.neyts@kuleuven.be.
Biochem Biophys Res Commun ; 555: 134-139, 2021 05 28.
Article em En | MEDLINE | ID: mdl-33813272

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Cisteína Proteinase / Modelos Animais de Doenças / Amidas / Proteases 3C de Coronavírus / SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: Biochem Biophys Res Commun Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Cisteína Proteinase / Modelos Animais de Doenças / Amidas / Proteases 3C de Coronavírus / SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: Biochem Biophys Res Commun Ano de publicação: 2021 Tipo de documento: Article